Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have been assigned a consensus rating of “Moderate Buy” from the eight analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $55.50.

A number of research analysts have weighed in on TVRD shares. Lucid Cap Mkts raised shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Weiss Ratings reiterated a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Monday, December 29th. Cantor Fitzgerald cut Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 13th. Wall Street Zen downgraded Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 23rd. Finally, Barclays set a $5.00 price target on shares of Tvardi Therapeutics and gave the company an “equal weight” rating in a research report on Monday, October 13th.

Tvardi Therapeutics Stock Down 2.3%

Shares of TVRD opened at $3.86 on Thursday. Tvardi Therapeutics has a 52-week low of $3.74 and a 52-week high of $43.65. The stock has a market cap of $36.21 million, a PE ratio of -0.40 and a beta of 0.14. The firm’s fifty day moving average is $4.22 and its two-hundred day moving average is $15.61.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.24.

Institutional Trading of Tvardi Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in TVRD. Geode Capital Management LLC purchased a new stake in shares of Tvardi Therapeutics during the 2nd quarter valued at approximately $2,617,000. JPMorgan Chase & Co. purchased a new stake in Tvardi Therapeutics in the second quarter valued at $39,000. New York State Common Retirement Fund purchased a new stake in Tvardi Therapeutics in the second quarter valued at $92,000. Marshall Wace LLP acquired a new position in shares of Tvardi Therapeutics in the 2nd quarter valued at $583,000. Finally, Slate Path Capital LP purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth $16,427,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.